Polymyositis and dermatomyositis historical perspective: Difference between revisions
Jump to navigation
Jump to search
m (Bot: Removing from Primary care) |
|||
| (5 intermediate revisions by one other user not shown) | |||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
In the late 19th century, polymyositis and dermatomyositis were described by different scientists. In 1916, Stertz was the first who described the association between dermatomyositis and [[Cancer|malignancy]]. In 1975, Anthony Bohan and James B. Peter were the first physicians who classified polymyositis and dermatomyositis into 5 subtypes which were used for decades. By 1990, multiple myositis-specific autoantibodies (MSA) were discovered and described. These myositis-specific autoantibodies (MSA) targeting different [[Cytoplasm|cytoplasmic]] ribonucleoproteins and they are used by Love et al. to classify polymyositis and dermatomyositis. | |||
==Historical Perspective== | ==Historical Perspective== | ||
===Discovery=== | ===Discovery=== | ||
* | *In 1863 and 1887, Ernst Leberecht Wagner described polymyositis and dermatomyositis (also known as Unverricht-Wagner or Wagner-Unverricht syndrome) in two publications.<ref name="KeitelWolff2015">{{cite journal|last1=Keitel|first1=W.|last2=Wolff|first2=H.-P.|title=Erstbeschreiber und Namensgeber der Dermatomyositis|journal=Zeitschrift für Rheumatologie|volume=75|issue=4|year=2015|pages=429–434|issn=0340-1855|doi=10.1007/s00393-015-0008-8}}</ref> | ||
*In 1875, Potain was the first who published a case of dermatomyositis documented in Europe.<ref name="DalakasHohlfeld2003">{{cite journal|last1=Dalakas|first1=Marinos C|last2=Hohlfeld|first2=Reinhard|title=Polymyositis and dermatomyositis|journal=The Lancet|volume=362|issue=9388|year=2003|pages=971–982|issn=01406736|doi=10.1016/S0140-6736(03)14368-1}}</ref> | *In 1875, Potain was the first who published a case of dermatomyositis documented in Europe.<ref name="DalakasHohlfeld2003">{{cite journal|last1=Dalakas|first1=Marinos C|last2=Hohlfeld|first2=Reinhard|title=Polymyositis and dermatomyositis|journal=The Lancet|volume=362|issue=9388|year=2003|pages=971–982|issn=01406736|doi=10.1016/S0140-6736(03)14368-1}}</ref> | ||
*In 1886, Urivericht was the first who described polymyositis.<ref name=" | *In 1886, Urivericht was the first who described polymyositis.<ref name="DalakasHohlfeld2003">{{cite journal|last1=Dalakas|first1=Marinos C|last2=Hohlfeld|first2=Reinhard|title=Polymyositis and dermatomyositis|journal=The Lancet|volume=362|issue=9388|year=2003|pages=971–982|issn=01406736|doi=10.1016/S0140-6736(03)14368-1}}</ref> | ||
*In 1916, Stertz was the first who described the association between dermatomyositis and [[Cancer|malignancy]].<ref name="TiniakouMammen2015">{{cite journal|last1=Tiniakou|first1=Eleni|last2=Mammen|first2=Andrew L.|title=Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review|journal=Clinical Reviews in Allergy & Immunology|volume=52|issue=1|year=2015|pages=20–33|issn=1080-0549|doi=10.1007/s12016-015-8511-x}}</ref> | |||
*In 1975, Anthony Bohan and James B. Peter were the first physicians who classified polymyositis and dermatomyositis into 5 subtypes which include:<ref name="pmid29550929">{{cite journal |vauthors=Leclair V, Lundberg IE |title=New Myositis Classification Criteria-What We Have Learned Since Bohan and Peter |journal=Curr Rheumatol Rep |volume=20 |issue=4 |pages=18 |date=March 2018 |pmid=29550929 |pmc=5857275 |doi=10.1007/s11926-018-0726-4 |url=}}</ref> | *In 1975, Anthony Bohan and James B. Peter were the first physicians who classified polymyositis and dermatomyositis into 5 subtypes which include:<ref name="pmid29550929">{{cite journal |vauthors=Leclair V, Lundberg IE |title=New Myositis Classification Criteria-What We Have Learned Since Bohan and Peter |journal=Curr Rheumatol Rep |volume=20 |issue=4 |pages=18 |date=March 2018 |pmid=29550929 |pmc=5857275 |doi=10.1007/s11926-018-0726-4 |url=}}</ref> | ||
**Primary idiopathic polymyositis (PM) | **Primary idiopathic polymyositis (PM) | ||
**Primary idiopathic dermatomyositis (DM) | **Primary idiopathic dermatomyositis (DM) | ||
**DM/PM associated with neoplasia | **DM/PM associated with [[neoplasia]] | ||
**Childhood DM/PM associated with vasculitis | **Childhood DM/PM associated with [[vasculitis]] | ||
**DM/PM with associated collagen-vascular disease | **DM/PM with associated [[Connective tissue disease|collagen-vascular disease]] | ||
*By 1990, seven myositis-specific autoantibodies (MSA) were discovered and described. These myositis-specific autoantibodies (MSA) targeting different cytoplasmic ribonucleoproteins including: | |||
*By 1990, seven myositis-specific autoantibodies (MSA) were discovered and described. These myositis-specific autoantibodies (MSA) targeting different cytoplasmic ribonucleoproteins including | **[[Helicase]] protein (Mi2) | ||
**Helicase protein (Mi2) | **[[Signal recognition particle]] ([[SRP receptor|SRP]]) | ||
**Signal recognition particle (SRP) | **Anti-aminoacyl-tRNA synthetases such as: | ||
**Anti-aminoacyl-tRNA synthetases such as | |||
***Histidyl (Jo1) | ***Histidyl (Jo1) | ||
***Threonyl (PL-7) | ***Threonyl (PL-7) | ||
| Line 34: | Line 30: | ||
***Isoleucyl (OJ) | ***Isoleucyl (OJ) | ||
*In 1991, Love et al. proposed another classification of idiopathic inflammatory myopathy based on myositis-specific autoantibodies (MSA). | *In 1991, Love et al. proposed another classification of idiopathic inflammatory myopathy based on myositis-specific autoantibodies (MSA). | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Medicine]] | |||
[[Category:Rheumatology]] | |||
[[Category:Dermatology]] | |||
[[Category:Up-To-Date]] | |||
Latest revision as of 23:47, 29 July 2020
|
Polymyositis and dermatomyositis Microchapters |
|
Differentiating Polymyositis and dermatomyositis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Polymyositis and dermatomyositis historical perspective On the Web |
|
American Roentgen Ray Society Images of Polymyositis and dermatomyositis historical perspective |
|
FDA on Polymyositis and dermatomyositis historical perspective |
|
CDC on Polymyositis and dermatomyositis historical perspective |
|
Polymyositis and dermatomyositis historical perspective in the news |
|
Blogs on Polymyositis and dermatomyositis historical perspective |
|
Risk calculators and risk factors for Polymyositis and dermatomyositis historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
In the late 19th century, polymyositis and dermatomyositis were described by different scientists. In 1916, Stertz was the first who described the association between dermatomyositis and malignancy. In 1975, Anthony Bohan and James B. Peter were the first physicians who classified polymyositis and dermatomyositis into 5 subtypes which were used for decades. By 1990, multiple myositis-specific autoantibodies (MSA) were discovered and described. These myositis-specific autoantibodies (MSA) targeting different cytoplasmic ribonucleoproteins and they are used by Love et al. to classify polymyositis and dermatomyositis.
Historical Perspective
Discovery
- In 1863 and 1887, Ernst Leberecht Wagner described polymyositis and dermatomyositis (also known as Unverricht-Wagner or Wagner-Unverricht syndrome) in two publications.[1]
- In 1875, Potain was the first who published a case of dermatomyositis documented in Europe.[2]
- In 1886, Urivericht was the first who described polymyositis.[2]
- In 1916, Stertz was the first who described the association between dermatomyositis and malignancy.[3]
- In 1975, Anthony Bohan and James B. Peter were the first physicians who classified polymyositis and dermatomyositis into 5 subtypes which include:[4]
- Primary idiopathic polymyositis (PM)
- Primary idiopathic dermatomyositis (DM)
- DM/PM associated with neoplasia
- Childhood DM/PM associated with vasculitis
- DM/PM with associated collagen-vascular disease
- By 1990, seven myositis-specific autoantibodies (MSA) were discovered and described. These myositis-specific autoantibodies (MSA) targeting different cytoplasmic ribonucleoproteins including:
- Helicase protein (Mi2)
- Signal recognition particle (SRP)
- Anti-aminoacyl-tRNA synthetases such as:
- Histidyl (Jo1)
- Threonyl (PL-7)
- Alanyl (PL-12)
- Glycyl (EJ)
- Isoleucyl (OJ)
- In 1991, Love et al. proposed another classification of idiopathic inflammatory myopathy based on myositis-specific autoantibodies (MSA).
References
- ↑ Keitel, W.; Wolff, H.-P. (2015). "Erstbeschreiber und Namensgeber der Dermatomyositis". Zeitschrift für Rheumatologie. 75 (4): 429–434. doi:10.1007/s00393-015-0008-8. ISSN 0340-1855.
- ↑ 2.0 2.1 Dalakas, Marinos C; Hohlfeld, Reinhard (2003). "Polymyositis and dermatomyositis". The Lancet. 362 (9388): 971–982. doi:10.1016/S0140-6736(03)14368-1. ISSN 0140-6736.
- ↑ Tiniakou, Eleni; Mammen, Andrew L. (2015). "Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review". Clinical Reviews in Allergy & Immunology. 52 (1): 20–33. doi:10.1007/s12016-015-8511-x. ISSN 1080-0549.
- ↑ Leclair V, Lundberg IE (March 2018). "New Myositis Classification Criteria-What We Have Learned Since Bohan and Peter". Curr Rheumatol Rep. 20 (4): 18. doi:10.1007/s11926-018-0726-4. PMC 5857275. PMID 29550929.